Dr. Gabrail is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4875 Higbee Ave NW
Canton, OH 44718Phone+1 330-492-3345Fax+1 330-492-0462
Summary
- Founder of Gabrail Cancer Center. Active in clinical research and new anticancer drug development. Special interes in family cancer syndromes and cancer genetics.
Published the book "Good Medicine is Cheaper Medicine"
Education & Training
- SSM Health/Saint Louis University School of MedicineFellowship, Hematology and Medical Oncology, 1987 - 1998
- Hurley Medical Center/Michigan State UniversityResidency, Internal Medicine, 1985 - 1986
- University of Mosul College of MedicineClass of 1976
Certifications & Licensure
- OH State Medical License 1990 - 2027
- NC State Medical License 2021 - 2022
- IA State Medical License 2016 - 2020
- MI State Medical License 1985 - 1998
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012-2013
Clinical Trials
- Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Start of enrollment: 2003 Jan 01
- Safety and Efficacy Study of Glufosfamide in Ovarian Cancer Start of enrollment: 2007 Jan 01
- Forodesine in the Treatment of Cutaneous T-Cell Lymphoma Start of enrollment: 2007 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 1370 citationsRelationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal CancerSteven J. Cohen, Cornelis J A Punt, Nicholas Iannotti, B. H. Saidman, Kert D. Sabbath
Journal of Clinical Oncology. 2008-07-01 - 31 citationsTilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma.Cara Haymaker, Daniel H. Johnson, Ravi Murthy, Salah-Eddine Bentebibel, Marc Uemura
Cancer Discovery. 2021-01-01 - 241 citationsEffects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trialAdrian S. Dobs, Ralph V Boccia, Christopher Charles Croot, Nashat Y Gabrail, James T. Dalton
The Lancet. Oncology. 2013-04-01
Abstracts/Posters
- Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ...Nashat Y. Gabrail, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phleb...Nashat Gabrail, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
- Transcenta to Present Two Phase I Clinical Trials of TST001 at Upcoming ASCO GI and IGCCJanuary 12th, 2022
- Intravenous Iron Replacement Therapy for Iron Deficiency Anemia in AdultsJanuary 1st, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: